|Intra Cellular Therapies -- USA Stock|| |
USD 19.10 0.36 1.85%
Vice President - Corporate Communications and Investor Relations
Dr. Juan F. Sanchez, M.D., is Vice President Corporationrationrate Communications of IntraCellular Therapies, Inc. Previously, he was a healthcare research analyst at investment banking firm Ladenburg Thalmann Co. Inc., with a deep focus on companies specializing in central nervous system diseases from 2008 to 2014, most recently as a Managing Director. Prior to that time, he was a Vice President of healthcare and nanotechnology equity research at investment banking firm Punk, Ziegel, Co. Dr. Sanchez received his Master in International Affairs from Columbia University and his MBA from University of Los Andes in Bogota, Colombia. Dr. Sanchez practiced medicine for five years in his native country, Colombia, having received a medical degree from Pontifical Xavierian University, in Bogota.
Age: 43 President Since 2014
The company has return on total asset (ROA)
of (14.94) %
which means that it has lost $14.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (23.56) %
meaning that it created substantial loss on money invested by shareholders.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.
Intra Cellular Thera Leadership Team
|Lawrence Wennogle, President, Ph.D|
|Christopher Alafi, Director|
|Michael Rawlins, Director|
|Robert Nostrand, Director|
|Richard Lerner, Director|
|Robert Davis, President, Ph.D|
|Allen Fienberg, Founder, Ph.D|
|Michael Halstead, SVP|
|Sharon Mates, Chairman, Ph.D|
|Andrew Satlin, President|
|Juan Sanchez, President|
|Rory Riggs, Director, MBA|
|Joel Marcus, Director|
|Kimberly Vanover, VP, Ph.D|
|Lawrence Hineline, President, CPA|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Intra Cellular Therapies. What is your judgment towards investing in Intra Cellular Therapies? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations